Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo

• Published in: ACS central science Vol. 8; no. 9; pp. 1238 - 1257
• Main Authors: Najer, Adrian, Blight, Joshua, Ducker, Catherine B., Gasbarri, Matteo, Brown, Jonathan C., Che, Junyi, Høgset, Håkon, Saunders, Catherine, Ojansivu, Miina, Lu, Zixuan, Lin, Yiyang, Yeow, Jonathan, Rifaie-Graham, Omar, Potter, Michael, Tonkin, Renée, Penders, Jelle, Doutch, James J., Georgiadou, Athina, Barriga, Hanna M. G., Holme, Margaret N., Cunnington, Aubrey J., Bugeon, Laurence, Dallman, Margaret J., Barclay, Wendy S., Stellacci, Francesco, Baum, Jake, Stevens, Molly M.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 28.09.2022
• Subjects: Medicin och hälsovetenskap
• ISSN: 2374-7943; 2374-7951
• DOI: 10.1021/acscentsci.1c01368

Infectious diseases continue to pose a substantial burden on global populations, requiring innovative broad-spectrum prophylactic and treatment alternatives. Here, we have designed modular synthetic polymer nanoparticles that mimic functional components of host cell membranes, yielding multivalent nanomimics that act by directly binding to varied pathogens. Nanomimic blood circulation time was prolonged by reformulating polymer–lipid hybrids. Femtomolar concentrations of the polymer nanomimics were sufficient to inhibit herpes simplex virus type 2 (HSV-2) entry into epithelial cells, while higher doses were needed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given their observed virustatic mode of action, the nanomimics were also tested with malaria parasite blood-stage merozoites, which lose their invasive capacity after a few minutes. Efficient inhibition of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical rodent malaria model. We envision these nanomimics forming an adaptable platform for developing pathogen entry inhibitors and as immunomodulators, wherein nanomimic-inhibited pathogens can be secondarily targeted to sites of immune recognition.